Media Room
As a leader in the provision of innovative treatments, Wyeth can provide a unique contribution to media stories and commentary particularly in the area of infectious disease, antibiotic resistance, child nutrition and immunisation, women's health, arthritis and mental health. In addition, Wyeth has a number of established relationships with specialists and doctors who at times may be available to talk to the media about important health issues.
As a member of Medicines Australia, Wyeth's interactions with the media are governed by the industry code of conduct. For more information or to obtain a copy of the Medicines Australia Code of Conduct please visit www.medicinesaustralia.com.au.
Contact the media team
Peter Poggioli
Associate Director Corporate Affairs
Tel: 61 2 8850 8239
Mobile:0404 555 025
PBAC Responses Wyeth response to July 2008 Pharmaceutical Benefits Advisory Committee (PBAC) decision on Enbrel (etanercept) for treatment of rheumatoid arthritis and psoriatic arthritis. More> Wyeth response to July 2008 Pharmaceutical Benefits Advisory Committee (PBAC) decision on Enbrel (etanercept) for treatment of chronic plaque psoriasis. More> |
- Research & Development
- Globally Wyeth is renowned for its extensive research agenda and Wyeth Australia’s research and development team contributes significantly to this effort in a number of therapeutic areas. These include rheumatology, dermatology, oncology, anti-infectives, solid organ transplantation, neurology, haematology, osteoporosis, vaccines and women’s health. More>
